ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

DCPC Board Okays Concept For $10 Mil. Program to Promote Cancer Management In Rural Areas

May 25, 1990

Early ADT Doesn’t Offer Survival Advantage—ASCO

April 27, 2007

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

June 28, 2013

NCI Clarifies IRPG Application Receipt, Funding Policies

September 3, 1993

Brain Gliomas Progress When Gene Function Is Lost

April 25, 2003

SWOG Wins NCI Grant Renewal For Six Years

April 16, 2010